Human Embryonic Stem Cells Market Size, Share & Trends Analysis Report By Application (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing), By Region, And Segment Forecasts, 2024 - 2030

Human Embryonic Stem Cells Market Trends

The global human embryonic stem cells market size was valued at USD 2.02 billion in 2023 and is projected to grow at a CAGR of 10.5% from 2024 to 2030. The demand for stem cells is high mainly due to the rising prevalence of chronic and malignant diseases. The ongoing research on regenerative medicine and stem cell therapies has fueled the demand for regenerative therapies for age-related diseases. Government support for cancer research and stem cell therapies to treat malignancies positively influences the market conditions.

Stem cell therapies have grown at an exponential rate in recent years. Therapies such as hematopoietic stem cells (HSC), induced pluripotent stem cells (iPSC), and mesenchymal stem cells (MSC) have garnered much attention. Human embryonic stem cells have two primary characteristics: potency and self-renewal. Potency refers to the potential to modify in various end-cells; self-renewal is the ability to multiply significantly. The participation of clinical institutions and private companies along with government funding encourages the research on stem cells. The growing interest in cell culture and regenerative medicine has augmented the viability of research for these treatments.

The favorable policies by the governing bodies catalyze the research process and foster a conducive environment for these activities. Novel treatments for autoimmune, fertility, cardiovascular, and neurological disorders have opened new avenues for cell-based research with patient-centric treatments. For instance, induced pluripotent stem cells (iPSCs) are used for several applications that follow the patient’s genetic design. They are even used for cytotoxicity studies and disease modeling.

Several other factors such as the need for treating life-threatening disorders, growing demand for stem cell banking, a tremendous rise in the geriatric population, and clinical support encourage significant developments in the healthcare sector. The researchers have witnessed a growing number of stem cell banks and potentially engaging therapies for stem cells. iPSCs offer numerous growth opportunities for the market and emerge as an alternative for human embryonic stem cells.

Application Insights

Regenerative medicines dominated the market with a share of 61.1% in 2023. Regenerative medicines offer significant advancements in treating several diseases. Moreover, pluripotent cells originating from human embryos have been central to biomedical research. However, the complex regulations in the clinical domain have limited their applications to human embryos. On the other hand, hESCs have exhibited a huge potential for preclinical studies in areas such as neurology, ophthalmology, reproductive medicine, and others.

The stem cell biology research segment is expected to witness the fastest CAGR of 11.4% over the forecast period. Several biopharmaceutical companies have explored the potency of stem cell biology in the past. Specifically, the study of stem cells in cancer and neurological research has resulted in potent drug discoveries and novel treatments. Stem cells have emerged as a treatment solution for Parkinson’s and Alzheimer’s in the geriatric population. In addition, gene editing technology and 3D bioprinting have opened new avenues for stem cell biology.

Regional Insights

North America human embryonic stem cells dominated the market in 2023 owing to robust research infrastructure institutions and facilities. The rise in chronic diseases and genetic disorders has created a huge demand for gene therapies. Moreover, government policies and regulations also streamline the effectiveness of stem cells for complex treatments. Extensive collaboration among clinical institutions and research biotech companies has propelled the regional market growth.

U.S. Human Embryonic Stem Cell Market Trends

The U.S. human embryonic stem cells market dominated the North American market with a substantial revenue share in 2023. As the U.S. healthcare sector is significantly driven by technological advancements, regulatory changes, and shifts in approaching gene therapies, the framework for stem cell therapy is likely to evolve significantly. Other factors such as growth in cell preservation techniques, rise in healthcare expenditure, growing acceptance of regenerative medicine, and a rising number of regulatory approvals are anticipated to drive the market.

Europe Human Embryonic Stem Cell Market Trends

Europe human embryonic stem cell market was identified as a lucrative region in 2023. Stem cell therapies have received positive attention in the European countries. It emerges to be one of the most promising areas of biotechnology, with the development of new methods to replace or repair damaged cells or tissues. Moreover, stem cell therapies have delivered positive outcomes for patients with chronic diseases such as cancer, stroke, spinal cord injuries, and diabetes. Therefore, the regional market continues to advance in the event of a growing geriatric population, and medical needs.

Asia Pacific Human Embryonic Stem Cells Market Trends

Asia Pacific human embryonic stem cell market is anticipated to witness significant growth in the forecast period. China, Japan, South Korea, and India are leading the way in promoting regenerative therapies and fostering innovation through government-led initiatives. The focus on clinical research and government funding for research projects in stem cell therapies has fueled the expansion of human embryonic stem cell therapies in Asia Pacific. Increasing medical tourism and collaborations between international healthcare agencies and Asian governments contribute to the popularity of stem cell therapies and regenerative medicines in the region.

Key Human Embryonic Stem Cells Company Insights

Some key players in the market include Thermo Fisher Scientific, Inc.; STEMCELL Technologies, CellGenix GmbH, ESI BIO, PromoCell GmbH, Lonza, and International Stem Cell Corporation.

• Thermo Fisher Scientific, Inc. offers a broad range of products and services to support stem cell research and applications. The company provides advanced tools for stem cell characterization, including flow cytometry kits, immunocytochemistry reagents, and gene expression assays.

• STEMCELL Technologies specializes in developing and manufacturing cell culture media and cell isolation systems. The company offers innovative tools and services for stem cells, immunology, cancer, regenerative medicines, and cellular therapy research. Their product portfolio includes a wide range of cell culture media optimized for various stem cell types, including embryonic, induced pluripotent, and adult stem cells.

Recent Developments

• In January 2024, Stemcell Technologies announced the acquisition of Propagenix Inc. This acquisition is significant to Stemcell’s growth journey. The merger is expected to propel advances in scientific research in labs and clinical settings in treating various diseases.

• In October 2023, Sartorius CellGenix designed a new facility to meet the ever-growing demand for high-quality material in the cell and gene therapy market. The specifications include the laboratories and production rooms spread over 10,000 square meters.

Human Embryonic Stem Cells Market Scope

Global Human Embryonic Stem Cells Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global human embryonic stem cells market report based on application, and region:

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Regenerative Medicine

  • Stem Cell Biology Research

  • Tissue Engineering

  • Toxicology Testing

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • Saudi Arabia

    • Kuwait

    • UAE

    • South Africa